2.11
price up icon2.10%   0.04
 
loading
전일 마감가:
$2.07
열려 있는:
$2.02
하루 거래량:
134.62K
Relative Volume:
0.54
시가총액:
$41.18M
수익:
-
순이익/손실:
$-30.26M
주가수익비율:
-1.0343
EPS:
-2.04
순현금흐름:
$-24.69M
1주 성능:
-3.50%
1개월 성능:
-8.51%
6개월 성능:
+41.84%
1년 성능:
-73.35%
1일 변동 폭
Value
$2.02
$2.12
1주일 범위
Value
$1.8782
$2.20
52주 변동 폭
Value
$1.11
$10.54

Annovis Bio Inc Stock (ANVS) Company Profile

Name
명칭
Annovis Bio Inc
Name
전화
484-875-3192
Name
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Name
직원
6
Name
트위터
Name
다음 수익 날짜
2024-12-11
Name
최신 SEC 제출 서류
Name
ANVS's Discussions on Twitter

ANVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ANVS
Annovis Bio Inc
2.1134 40.34M 0 -30.26M -24.69M -2.04
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
406.74 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.25 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
461.91 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
772.25 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
344.91 37.42B 3.81B -644.79M -669.77M -6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-10 다운그레이드 D. Boral Capital Buy → Hold
2024-10-25 업그레이드 Maxim Group Hold → Buy
2023-12-29 개시 Canaccord Genuity Buy
2021-07-07 재확인 Maxim Group Buy

Annovis Bio Inc 주식(ANVS)의 최신 뉴스

pulisher
04:47 AM

Why analysts raise outlook for Annovis Bio Inc. stockWeekly Market Report & Precise Entry and Exit Recommendations - newser.com

04:47 AM
pulisher
Sep 30, 2025

How high can Annovis Bio Inc. stock goTrend Reversal & Daily Momentum Trading Reports - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Why Annovis Bio Inc. stock is considered a top pick2025 Investor Takeaways & Community Consensus Trade Signals - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Canaccord Genuity Maintains Annovis Bio (ANVS) Buy Recommendation - Nasdaq

Sep 30, 2025
pulisher
Sep 30, 2025

Canaccord Genuity reaffirms Buy rating on Annovis Bio stock By Investing.com - Investing.com Australia

Sep 30, 2025
pulisher
Sep 30, 2025

Canaccord Genuity reaffirms Buy rating on Annovis Bio stock - Investing.com India

Sep 30, 2025
pulisher
Sep 29, 2025

Annovis Bio completes $21 million stock and warrant offering - MSN

Sep 29, 2025
pulisher
Sep 29, 2025

Is Annovis Bio Inc. stock in buy zone after pullbackJuly 2025 Weekly Recap & Low Risk Investment Opportunities - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Can IKIO Lighting Limited Achieve Earnings Growth in a SlowdownMarket Liquidity Analysis & AI-Based Predictions Available Free - earlytimes.in

Sep 29, 2025
pulisher
Sep 29, 2025

Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN

Sep 29, 2025
pulisher
Sep 29, 2025

Does Annovis Bio Inc. show high probability of rebound2025 Price Momentum & Breakout Confirmation Alerts - newser.com

Sep 29, 2025
pulisher
Sep 27, 2025

Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MSN

Sep 27, 2025
pulisher
Sep 26, 2025

Why Annovis Bio Inc. stock stays on buy listsWeekly Volume Report & Entry and Exit Point Strategies - newser.com

Sep 26, 2025
pulisher
Sep 26, 2025

Annovis Bio Appoints Mark Guerin as CFO to Guide Late-Stage Neurodegenerative Drug Development - citybuzz -

Sep 26, 2025
pulisher
Sep 25, 2025

Down Syndrome Market: Epidemiology, Therapies, Companies, DelveInsight | AC Immune, Annovis Bio, Alzheon, OPKO Health, Inc., Aelis Farma - Barchart.com

Sep 25, 2025
pulisher
Sep 25, 2025

Annovis Bio names Mark Guerin as new chief financial officer By Investing.com - Investing.com Australia

Sep 25, 2025
pulisher
Sep 25, 2025

Annovis Bio names Mark Guerin as new chief financial officer - Investing.com India

Sep 25, 2025
pulisher
Sep 25, 2025

Annovis Bio Appoints Mark Guerin as Chief Financial Officer to Support Late-Stage Development of Buntanetap - Quiver Quantitative

Sep 25, 2025
pulisher
Sep 25, 2025

Annovis Appoints Mark Guerin as Chief Financial Officer - The Manila Times

Sep 25, 2025
pulisher
Sep 25, 2025

Neurodegenerative Drug Developer Annovis Bio Strengthens Leadership with Veteran Biotech CFO Appointment - Stock Titan

Sep 25, 2025
pulisher
Sep 22, 2025

Pattern recognition hints at Annovis Bio Inc. upside2025 Analyst Calls & AI Driven Price Predictions - newser.com

Sep 22, 2025
pulisher
Sep 20, 2025

Earnings Beat: Is CARS a top pick in the sectorQuarterly Market Review & Daily Growth Stock Tips - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Bear Alert: Will Annovis Bio Inc. benefit from government policyGap Down & Smart Investment Allocation Insights - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate - MyChesCo

Sep 20, 2025
pulisher
Sep 20, 2025

Annovis Bio up 5% as FDA clears phase 3 buntanetap program for Alzheimer's - MSN

Sep 20, 2025
pulisher
Sep 19, 2025

Volatility Watch: What is the implied volatility of Annovis Bio IncJuly 2025 Levels & Consistent Growth Stock Picks - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Aug Volume: Can Brookfield Business Corporation beat the S&P 500Earnings Miss & Risk Managed Investment Strategies - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Using data filters to optimize entry into Annovis Bio Inc.2025 Valuation Update & Precise Buy Zone Tips - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Block Trades: Should you avoid Annovis Bio Inc. stock right nowJuly 2025 Retail & Weekly High Return Forecasts - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Aug Spikes: Will Annovis Bio Inc stock recover after earningsDividend Hike & Low Drawdown Trading Techniques - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Analyzing recovery setups for Annovis Bio Inc. investorsOptions Play & Risk Controlled Stock Pick Alerts - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Growth Recap: Will Annovis Bio Inc outperform the market in YEARWeekly Trade Analysis & Smart Investment Allocation Insights - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Will breakout in Annovis Bio Inc. lead to full recoveryWeekly Risk Summary & Community Verified Trade Signals - newser.com

Sep 19, 2025
pulisher
Sep 18, 2025

Aug Momentum: Will Annovis Bio Inc benefit from government policyMarket Growth Summary & Safe Capital Growth Plans - khodrobank.com

Sep 18, 2025
pulisher
Sep 18, 2025

Annovis Bio Inc. stock trend outlook and recovery pathWeekly Investment Report & Fast Entry Momentum Alerts - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Risks Report: What is HOLOWs 5 year growth outlook2025 Pullback Review & Reliable Momentum Entry Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 18, 2025

Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN

Sep 18, 2025
pulisher
Sep 18, 2025

Applying Elliott Wave Theory to Annovis Bio Inc.2025 Risk Factors & Fast Gain Stock Tips - newser.com

Sep 18, 2025
pulisher
Sep 18, 2025

Is it time to cut losses on Annovis Bio Inc.July 2025 Setups & High Accuracy Investment Signals - newser.com

Sep 18, 2025
pulisher
Sep 17, 2025

Can trapped investors hope for a rebound in Annovis Bio Inc.2025 Market Sentiment & Free Technical Confirmation Trade Alerts - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Is Annovis Bio Inc. showing signs of accumulation2025 Market Outlook & Expert Curated Trade Setups - newser.com

Sep 17, 2025
pulisher
Sep 17, 2025

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap - markets.businessinsider.com

Sep 17, 2025
pulisher
Sep 17, 2025

Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN

Sep 17, 2025
pulisher
Sep 16, 2025

Aug Macro: Can Annovis Bio Inc disrupt its industryMarket Movers & Weekly High Return Forecasts - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

US Market Wrap: Is Annovis Bio Inc a defensive stockJuly 2025 Decliners & AI Driven Price Forecasts - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Nasdaq Moves: Is BLCO affected by consumer sentimentJuly 2025 Recap & Stepwise Trade Signal Implementation - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Annovis Bio, Inc. Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap - MarketScreener

Sep 16, 2025
pulisher
Sep 16, 2025

Annovis Bio Publishes Findings on New Crystal Form of Buntanetap in Peer-Reviewed Journal, Supporting Phase 3 Trial in Alzheimer’s Disease - Quiver Quantitative

Sep 16, 2025
pulisher
Sep 16, 2025

New Crystal Form of Alzheimer's Drug Buntanetap Extends Patent Protection to 2040s, Matches Original - Stock Titan

Sep 16, 2025

Annovis Bio Inc (ANVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$35.83
price up icon 1.66%
$85.75
price up icon 1.10%
$31.46
price up icon 2.62%
$102.62
price up icon 4.05%
$144.22
price up icon 0.15%
biotechnology ONC
$342.98
price up icon 0.67%
자본화:     |  볼륨(24시간):